Researcher

Andong Li

Central South University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 12, 2026 · JOURNAL ARTICLE

Resmetirom for noncirrhotic metabolic dysfunction–associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany

Expert Review of Pharmacoeconomics & Outcomes Research

This is a modelling study that estimates hypothetical value-based prices; it does not report clinical trial data, real-world outcomes, or actual pricing decisions, and raises questions about pricing strategy rather than answering clinical or health-economic questions grounded in observed data.

Hypothesis-GeneratingMeiyu Wu Chongqing Tan Andong Li

Reported

Life-years gained (China)0.30

Life-years gained (UK)0.71

Life-years gained (France)0.96

AUG 10, 2026 · JOURNAL ARTICLE

Cost-effectiveness of targeted therapy versus chemotherapy for patients with advanced or metastatic gastric cancer in China

Frontiers in Pharmacology

A single-centre modelling study using a hybrid decision tree and Markov model with assumed parameters, not a clinical trial; provides economic perspective but lacks empirical validation of clinical inputs and generalizability.

PreliminaryMeiyu Wu Economic and Financial Impacts of Cancer Kehui Meng

Reported

Incremental cost$64,242.13

Incremental QALYs0.63

Incremental cost-effectiveness ra…$101,278.5/QALY